Hydrogel-based delivery of Tat-fused protein Hsp70 protects dopaminergic cells in vitro and in a mouse model of Parkinson’s disease
Source abstract
Abstract
Abstract Neurodegenerative disorders such as Parkinson’s disease (PD) have no effective therapies. However, many promising drugs are precluded from clinical trials because of their poor brain availability. The chaperone protein Hsp70 has been reported to be effective in PD models, but its brain targeting is challenging. We developed a novel brain Hsp70 delivery system using injectable, biocompatible, and biodegradable semi-interpenetrating polymer networks of collagen (COLL) and low-molecular-weight hyaluronic acid (LMW HA) structured with gelatin particles. We produced human recombinant Hsp70-1A fused with the cell-penetrating peptide Tat (Tat-Hsp70) that was neuroprotective in vitro against the dopaminergic toxin 6-hydroxydopamine (6-OHDA). We assessed Tat-Hsp70 release from the selected COLL-LMW HA composites in vitro, observing a 95% release of loaded protein after 96 h. The release kinetics FITTED the Korsmeyer-Peppas model (regression coefficient 0.98) and the released Tat-Hsp70 remained neuroprotective for SH-SY5Y cells. Magnetic resonance imaging revealed that COLL-LMW HA composites lasted at least 96 h at the brain level, and in vivo Tat-Hsp70 release studies indicated that hydrogel presence is pivotal for a spatially focused neuroprotective effect. In an in vivo model of dopaminergic degeneration, Tat-Hsp70-loaded composites conveyed neuroprotection at both the behavioral and dopaminergic neuronal levels against the striatal injection of 6-OHDA. After the injection of Tat-Hsp70-loaded composites, mice showed a transient inflammatory response, with a decrease in GFAP and CD11b immunostaining after 7 days. Our delivery system enabled the effective brain release of Tat-Hsp70 and is ready for further improvements.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Heat shock proteins research · Protein Structure and Dynamics · Viral Infectious Diseases and Gene Expression in Insects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Choonara, Y. E., Kumar, P., Modi, G. & Pillay, V. Improving drug delivery technology for treating neurodegenerative diseases. Expert. Opin. Drug. Deliv. 13, 1029–1043 (2016).10.1517/17425247.2016.1162152 ↗
2. Sharma, S. K. & Priya, S. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson’s disease. Cell. Mol. Life Sci. 74, 617–629 (2017).10.1007/s00018-016-2340-9 ↗
3. Pankratz, N. & Foroud, T. Genetics of Parkinson disease. NeuroRx 1, 235–242 (2004).10.1602/neurorx.1.2.235 ↗
4. Rizek, P., Kumar, N. & Jog, M. S. An update on the diagnosis and treatment of Parkinson disease. CMAJ 188, 1157–1165 (2016).10.1503/cmaj.151179 ↗
5. Auluck, P. K., Meulener, M. C. & Bonini, N. M. Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J. Biol. Chem. 280, 2873–2878 (2005).10.1074/jbc.M412106200 ↗
6. Yang, Q. et al. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 323, 124–127 (2009).10.1126/science.1166088 ↗
7. Fontaine, S. N., Martin, M. D. & Dickey, C. A. Neurodegeneration and the heat shock protein 70 machinery: implications for therapeutic development. Curr. Top. Med. Chem. 16, 2741–2752 (2016).10.2174/1568026616666160413140741 ↗
8. Lazarev, V. F. et al. Sensitizing tumor cells to conventional drugs: HSP70 chaperone inhibitors, their selection and application in cancer models. Cell Death Dis. 9, 41 (2018).10.1038/s41419-017-0160-y ↗
9. McFarland, N. R. et al. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. PLoS ONE 9, e86048 (2014).10.1371/journal.pone.0086048 ↗
10. Yurinskaya, M. M. et al. Encapsulated Hsp70 decreases endotoxin-induced production of ROS and TNFα in human phagocytes. Cell Stress Chaperon. 22, 163–171 (2017).10.1007/s12192-017-0777-x ↗
11. Shevtsov, M. A. et al. Neurotherapeutic activity of the recombinant heat shock protein Hsp70 in a model of focal cerebral ischemia in rats. Drug Des. Devel. Ther. 8, 639–650 (2014).10.2147/DDDT.S62024 ↗
12. Abkin, S. V., Pankratova, K. M., Komarova, E. Y., Guzhova, I. V. & Margulis, B. A. Hsp70 chaperone-based gel composition as a novel immunotherapeutic anti-tumor tool. Cell Stress Chaperon. 18, 391–396 (2013).10.1007/s12192-012-0391-x ↗
13. Lee, J., Tan, C. Y., Lee, S. K., Kim, Y. H. & Lee, K. Y. Controlled delivery of heat shock protein using an injectable microsphere/hydrogel combination system for the treatment of myocardial infarction. J. Control Release 137, 196–202 (2009).10.1016/j.jconrel.2009.04.008 ↗
14. Nagel, F. et al. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J. Neurochem. 105, 853–864 (2008).10.1111/j.1471-4159.2007.05204.x ↗
15. Nikolaeva, T. I., Tiktopulo, E. I., Polozov, R. V. & Rochev, Y. A. Thermodynamic characteristics of collagen fibrils reconstructed in vitro at different temperatures and concentrations. Biophysics 52, 191–195 (2007).10.1134/S000635090702008X ↗
16. Khaing, Z. Z. et al. High molecular weight hyaluronic acid limits astrocyte activation and scar formation after spinal cord injury. J. Neural Eng. 8, 046033 (2011).10.1088/1741-2560/8/4/046033 ↗
17. Sherman, L. S., Matsumoto, S., Su, W., Srivastava, T. & Back, S. A. Hyaluronan synthesis, catabolism, and signaling in neurodegenerative diseases. Int. J. Cell Biol. 2015, 368584 (2015).10.1155/2015/368584 ↗
18. Xin, X., Borzacchiello, A., Netti, P. A., Ambrosio, L. & Nicolais, L. Hyaluronic-acid-based semi-interpenetrating materials. J. Biomater. Sci. Polym. Ed. 15, 1223–1236 (2004).10.1163/1568562041753025 ↗
19. Oliveira, J. M. et al. Hydrogel-based scaffolds to support intrathecal stem cell transplantation as a gateway to the spinal cord: clinical needs, biomaterials, and imaging technologies. NPJ Regen. Med. 3, 8 (2018).10.1038/s41536-018-0046-3 ↗
20. Tsaryk, R. et al. Collagen-low molecular weight hyaluronic acid semi-interpenetrating network loaded with gelatin microspheres for cell and growth factor delivery for nucleus pulposus regeneration. Acta Biomater. 20, 10–21 (2015).10.1016/j.actbio.2015.03.041 ↗
21. Coester, C. J., Langer, K., van Briesen, H. & Kreuter, J. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J. Microencapsul. 17, 187–193 (2000).10.1080/026520400288427 ↗
22. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).10.1371/journal.pbio.1000412 ↗
23. Matambo, T. S., Odunuga, O. O., Boshoff, A. & Blatch, G. L. Overproduction, purification, and characterization of the Plasmodium falciparum heat shock protein 70. Protein Expr. Purif. 33, 214–222 (2004).10.1016/j.pep.2003.09.010 ↗
24. Nagel, F., Dohm, C. P., Bähr, M., Wouters, F. S. & Dietz, G. P. Quantitative evaluation of chaperone activity and neuroprotection by different preparations of a cell-penetrating Hsp70. J. Neurosci. Methods 171, 226–232 (2008).10.1016/j.jneumeth.2008.03.008 ↗
25. Luong, T. N., Carlisle, H. J., Southwell, A. & Patterson, P. H. Assessment of motor balance and coordination in mice using the balance beam. J. Vis. Exp. 49, 2376 (2011).
26. Klucken, J., Shin, Y., Masliah, E., Hyman, B. T. & McLean, P. J. Hsp70 reduces alpha-synuclein aggregation and toxicity. J. Biol. Chem. 279, 25497–25502 (2004).10.1074/jbc.M400255200 ↗
27. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. & Bonini, N. M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295, 865–868 (2002).10.1126/science.1067389 ↗
28. Dinca, A., Chien, W. & Chin, M. T. Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease. Int. J. Mol. Sci. 17, 263–275 (2016).10.3390/ijms17020263 ↗
29. Li, J. & Mooney, D. J. Designing hydrogels for controlled drug delivery. Nat. Rev. Mater. 1, 16071 (2016).10.1038/natrevmats.2016.71 ↗
30. Cooke, M. J., Wang, Y., Morshead, C. M. & Shoichet, M. S. Controlled epi-cortical delivery of epidermal growth factor for the stimulation of endogenous neural stem cell proliferation in stroke-injured brain. Biomaterials 32, 5688–5697 (2011).10.1016/j.biomaterials.2011.04.032 ↗
31. Tuladhar, A., Morshead, C. M. & Shoichet, M. S. Circumventing the blood-brain barrier: local delivery of cyclosporin A stimulates stem cells in stroke-injured rat brain. J. Control Release 215, 1–11 (2015).10.1016/j.jconrel.2015.07.023 ↗
32. Aleyasin, H. et al. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc. Natl Acad. Sci. USA 107, 3186–3191 (2010).10.1073/pnas.0914876107 ↗
33. Kim, H., Moodley, S. & Liu, M. TAT cell-penetrating peptide modulates inflammatory response and apoptosis in human lung epithelial cells. Drug Deliv. Transl. Res. 5, 275–278 (2015).10.1007/s13346-015-0230-6 ↗
34. Li, X. et al. A novel cell-penetrating peptide protects against neuron apoptosis after cerebral ischemia by inhibiting the nuclear translocation of annexin A1. Cell Death Differ. 26, 260–275 (2019).10.1038/s41418-018-0116-5 ↗
35. Kozai, T. D., Jaquins-Gerstl, A. S., Vazquez, A. L., Michael, A. C. & Cui, X. T. Brain tissue responses to neural implants impact signal sensitivity and intervention strategies. ACS Chem. Neurosci. 6, 48–67 (2015).10.1021/cn500256e ↗
36. Senthilkumar, K. S. et al. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. Behav. Brain. Res. 184, 11–18 (2007).10.1016/j.bbr.2007.06.025 ↗